Its Stock Has Paid Off Big Time For Biofrontera Inc.

Biofrontera Inc. (NASDAQ: BFRI) stock jumped 5.00% on Friday to $1.05 against a previous-day closing price of $1.00. With 0.25 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.75 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $1.1000 whereas the lowest price it dropped to was $1.0035. The 52-week range on BFRI shows that it touched its highest point at $14.63 and its lowest point at $0.86 during that stretch. It currently has a 1-year price target of $15.50.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BFRI was up-trending over the past week, with a rise of 13.76%, but this was down by -9.48% over a month. Three-month performance dropped to -41.67% while six-month performance fell -68.47%. A look at the trailing 12-month EPS for BFRI yields -3.01 with Next year EPS estimates of -0.59. For the next quarter, that number is -0.07. This implies an EPS growth rate of -211.80% for this year and -247.10% for next year.

Float and Shares Shorts:

At present, 18.82 million BFRI shares are outstanding with a float of 15.38 million shares on hand for trading. On Sep 14, 2022, short shares totaled 0.2 million, which was 0.84% higher than short shares on Aug 14, 2022. In addition to Dr. Hermann Lubbert Ph.D. as the firm’s Exec. Chairman & Pres, Ms. Erica L. Monaco CPA serves as its CEO, CFO, COO, Treasurer & Sec.

Institutional Ownership:

Through their ownership of 11.93% of BFRI’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 5.56% of BFRI, in contrast to 1.27% held by mutual funds. Shares owned by individuals account for 0.72%. As the largest shareholder in BFRI with 3.24% of the stake, Armistice Capital LLC holds 763,637 shares worth 763,637. A second-largest stockholder of BFRI, Bard Associates, Inc., holds 259,275 shares, controlling over 1.10% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in BFRI, holding 212,590 shares or 0.90% stake. With a 0.49% stake in BFRI, the Vanguard Extended Market Index Fu is the largest stakeholder. A total of 114,476 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 0.42% of BFRI stock, is the second-largest Mutual Fund holder. It holds 98,114 shares valued at 0.11 million. Fidelity Extended Market Index Fu holds 0.17% of the stake in BFRI, owning 39,403 shares worth 45707.0.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2022, BFRI reported revenue of $4.46M and operating income of -$8.11M. Over the past year, revenue came in at $27.71M while operating income stood at -$27.31M. It generated -$850.00k net income for the quarter, which came to -$25.81M over the last twelve months. The EBITDA in the recently reported quarter was -$7.90M and diluted EPS was -$0.05. EBITDA for the full year was -$30.17M.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BFRI since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BFRI analysts setting a high price target of $20.00 and a low target of $11.00, the average target price over the next 12 months is $15.50. Based on these targets, BFRI could surge 1804.76% to reach the target high and rise by 947.62% to reach the target low. Reaching the average price target will result in a growth of 1376.19% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. BFRI will report FY 2022 earnings on 04/07/2023. Analysts have provided yearly estimates in a range of -$0.09 being high and -$0.26 being low. For BFRI, this leads to a yearly average estimate of -$0.17. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Biofrontera Inc. surprised analysts by $0.29 when it reported -$0.05 EPS against a consensus estimate of -$0.34. The surprise factor in the prior quarter was $0.47. Based on analyst estimates, the high estimate for the next quarter is -$0.24 and the low estimate is -$0.32. The average estimate for the next quarter is thus -$0.28.

Leave a Comment

Your email address will not be published. Required fields are marked *




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam